Petros pharmaceuticals announces positive outcomes in label comprehension study for potential otc stendra label

Company well positioned to continue collaboration with fda toward pursuit of otc pathway for stendra new york, ny / accesswire / october 4, 2023 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over the counter (otc) nonprescription pathways, announces completion of a pivotal label comprehension study (lcs). using fda guidance provided to the company in 2022, the lcs is expected to satisfy a critical step in the organization's progress towards a possible non-prescription version of stendra, the company's prescription erectile dysfunction drug.
PTPI Ratings Summary
PTPI Quant Ranking